WO2014166029A1 - 针对表皮生长因子受体的抗体 - Google Patents
针对表皮生长因子受体的抗体 Download PDFInfo
- Publication number
- WO2014166029A1 WO2014166029A1 PCT/CN2013/073811 CN2013073811W WO2014166029A1 WO 2014166029 A1 WO2014166029 A1 WO 2014166029A1 CN 2013073811 W CN2013073811 W CN 2013073811W WO 2014166029 A1 WO2014166029 A1 WO 2014166029A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- egfr
- heavy chain
- functional fragment
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Definitions
- the present invention relates to novel epidermal growth factor receptor (EGFR) antibodies or functional fragments thereof and uses thereof.
- EGFR epidermal growth factor receptor
- the invention relates to fully human EGFR antibodies or functional fragments thereof.
- the invention also relates to methods of making the antibodies and to the use of the antibodies in the manufacture of a medicament for treating a tumor.
- Antibodies have been used to treat cancer as well as immunological or vascular diseases.
- the use of antibody-drug conjugates allows targeted delivery of drug moieties to tumors as well as other diseased tissues, while systemic administration of non-conjugated pharmaceutical agents may result in unacceptable levels of toxicity to normal cells.
- the basic unit of a native antibody is a monomer consisting of two identical heavy chains and two identical light chains joined by a disulfide bond. There are at least 5 different types of heavy chains, namely ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , which provide different effector functions.
- the amino acid sequence of the constant domain of their heavy chains natural Human antibodies can be classified into five classes: IgG, IgA, IgM, IgD, and IgE.
- the gG molecule consists of two heavy chain ⁇ and two identical light chains ( ⁇ or ⁇ ).
- the disulfide bond connects the light chain to the heavy chain as well as the heavy chain.
- the constant domain of the light chain and the first constant of the heavy chain domains to pair, variable domain variable domain (VL) and a light chain the heavy chain (V H) paired to form an antigen recognition site.
- VL variable domain variable domain
- V H light chain the heavy chain
- variable domain or variability in the whole domain Not uniformly distributed. Usually concentrated on three segments called hypervariable regions. The more conserved portion of the variable domain is called the framework region (FR).
- the variable domain contains 4 FRs, and the FR mainly adopts 3 hypervariables.
- a connected beta sheet structure that forms a loop connecting the beta sheet structure and, in some cases, a portion of the beta sheet structure.
- the hypervariable regions in each chain are closely adjacent by FR and are highly variable with the other strand The regions together are responsible for the formation of antigen binding sites for antibodies. See Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991).
- Epidermal growth factor receptor ( Epidermal growth factor receptor, EGFR, HER1, c -ErbBl) is a transmembrane glycoprotein consisting of 1186 amino acid residues with a molecular weight of 170 kD. EGFR is divided into three parts: the monthly package area, the cross-moon area, and the monthly package area (Jorissen RN, Walker F, Pouliot N, et al, Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 2003; 284: 31-53). EGFR belongs to the type I tyrosine kinase receptor subfamily (ErbB 1-4) and has tyrosine kinase activity.
- ErbB 1-4 tyrosine kinase receptor subfamily
- EGFR is stably expressed in many epithelial tissues, as well as interstitial and neurogenic tissues. Solid tumors in different organs also express high levels of EGFR, such as head and neck cancer, ovarian cancer, cervical cancer, bladder cancer and esophageal cancer (Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol, 2003; 21: 2787-2799).
- Growth factors such as transforming growth factor a (TGF a ) and epidermal growth factor ( EGF ) are ligands for EGFR.
- TGF a transforming growth factor a
- EGF epidermal growth factor
- the EerbB Signaling network receptor heterodimerzat ion in development and cancer.
- EGFR mediates these pathways to regulate normal cell growth and differentiation, increase tumor cell invasiveness, promote angiogenesis, and inhibit tumor cell apoptosis ( Castillo L, Etienne-Grimaldi MC, Fischel JL, et al. Pharmacological background of EGFR Targeting. Ann Oncol, 2004; 15: 1007-1012 ) 0
- the high expression of EGFR in tumors and its important role in tumor cell growth and differentiation make EGFR a promising tumor diagnosis and treatment. Target.
- EGFR epidermal growth factor receptor
- the highest rate of EGFR expression in various solid tumors is head and neck tumors, which range from 95% to 100%. Colorectal cancer is the second, with a rate of expression of 72%-89%.
- Tumors positive for EGFR expression are characterized by high malignancy and strong invasiveness, and the level of EGFR expression is associated with prognosis. Therefore, it has become an important target for current targeted therapy of tumor molecules. It is confirmed that HER1/EGFR is abnormally expressed in solid tumors, and its clinical manifestation is metastasis, shortened survival period, poor prognosis, and tolerant to chemotherapy and hormone therapy. Blocking HER1/EGFR inhibits tumor formation and improves the above.
- Tyrosine kinase antagonists are mainly small molecule quinoline compounds, which can competitively inhibit the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby affecting the phosphorylation of tyrosine residues and inhibiting the signal transduction downstream of EGFR. guide.
- EGFR monoclonal antibodies compete with endogenous ligands for EGFR, and produce anti-tumor effects by inhibiting the activation of tyrosine kinases and promoting EGFR internalization.
- three anti-EGFR monoclonal antibodies have been marketed at home and abroad. Compared with other chemotherapeutic drugs, these antibodies have strong specific effects, small side effects, and have achieved good therapeutic effects in the clinic.
- EGFR is a mature target for antibody drug development.
- anti-tumor antibody drugs HER2, EGFR, VEGF
- EGFR target-related targeted therapeutic drugs include antibody drugs in cancer therapy. Status is very important. Due to the limitations of anti-EGFR antibody drugs currently on the market, research and development of new anti-EGFR antibody drugs with high efficiency and low toxicity has been a hot spot in the international medical research.
- EGFR monoclonal antibody cetuximab binds to EGFR to block phosphorylation, inhibits ligand-activated EGFR tyrosine kinase activity, and promotes endocytosis and degradation of EGFR.
- cetuximab inhibits tumor cell growth by recruiting cells such as natural killer (NK) to the tumor surface
- NK natural killer
- Bleeker WK Lammerts van Bueren JJ, Van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Di jk MA, van de Winkel JG, Parren PW. Dual mode of act ion of a human anti-epidermal growth factor receptor monoclonal Antibody for cancer therapy. J Immunol. 2004; 173: 4699-707. ).
- the anti-GFR monoclonal and antibody effects in vivo are not only related to its affinity to EGFR, but also related to ADCC activity (Patel D, Guo X, Ng S, Melchior M, Balderes P, Bur T rum D, Per saud K, Luna X, Ludwig DL, Kang X.
- IgG isotype, glycosylation, and EGFR express ion determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
- Hum Antibodies. 2010; 19: 89- 99 0
- the conversion between IgG antibody subtypes can be achieved by antibody engineering techniques (Z Steplewski, LK Sun, CW Shearman, J Ghrayeb, P Daddona, and H Koprowski. Biological) Activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. PNAS 1988; 85 : 4852-4856 ) 0 At present, therapeutic monoclonal antibodies are divided into chimeric antibodies of about 70% human sequence, humanized antibodies of 90-94% human sequences, and fully human antibodies of 100% human sequences with the development of technology. kind.
- the proportion of human sequence means the possibility of immunogenicity when the antibody is used in human therapy. Therefore, the probability of immunogenicity of the fully human antibody is lower than that of the chimeric antibody, and it is used as a therapeutic drug.
- Source antibodies are superior to chimeric and humanized antibodies.
- ADCC antibody-dependent cel l-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity
- NK cells NK cells, macrophages, and neutrophils that express IgG-Fc receptors. Binding to the Fc segment of an I gG antibody on the surface of a target cell such as a virus-infected cell and a tumor cell kills the action of these target cells.
- IgG antibodies mediate the role of these cells in ADCC, which is the main cell that functions as ADCC.
- the antibody can only specifically bind to the corresponding antigenic epitope on the target cell, and effector cells such as NK cells can kill any target cell that has bound to the antibody, so the antibody and the target cell
- effector cells such as NK cells
- NK cells can kill any target cell that has bound to the antibody, so the antibody and the target cell
- the antigen binding on it is specific, and the killing effect of NK cells and the like on target cells is non-specific.
- Erbitux is a human-mouse chimeric IgG1 antibody which has a considerable degree of immunogenicity and is liable to produce a human anti-mouse antibody reaction with a large side effect, thereby affecting the drug effect.
- Panitumumab is a fully human IgG2 subtype antibody, but lacks the biological activity associated with ADCC (antibody-dependent cell-mediated cytotoxicity) and relies solely on blocking the EGFR signaling pathway to inhibit tumor growth without another The tumor suppressor mechanism of ADCC has a weak anti-tumor effect.
- panitumumab is altered from the IgG2 subtype to the IgGl subtype using an antibody engineering platform to form a novel sequence of anti-EGFR fully human antibody molecules having the same identity as panitumumab.
- the target binding characteristics, and due to different antibody subtypes, the antibody molecule has stronger ADCC biological activity, and has stronger anti-tumor effect than panitumumab.
- the antibody since the antibody is a fully human antibody molecule, its immunogenicity is lower than that of the chimeric antibody Erbitux, and the potential clinical application side effects are lower. Therefore, the antibody of the present invention brings together the advantages of the antibody known in the prior art, and an unexpected technical effect is obtained.
- the present invention provides novel anti-EGFR antibodies or functional fragments thereof which, on the one hand, reduce the immunogenic side effects of chimeric antibodies, and on the other hand, enhance the anti-tumor effect of antibodies by altering the subtypes of IgG antibodies.
- EGFR antibody a human-derived antibody that is capable of binding both EGFR and ADCC activity at a high level has never been obtained.
- the invention provides antibodies that convert an antibody subtype (eg, from IgG2 to IgG1).
- the invention also provides antibodies having optimized framework regions for the heavy and/or light chain variable regions.
- the invention provides an antibody or a functional fragment thereof that binds to EGFR, comprising a heavy chain and a light chain, wherein
- the heavy chain comprises a heavy chain variable region and a heavy chain constant region, wherein the heavy chain variable region has the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6, and the heavy chain is constant
- the region is the heavy chain constant region sequence of human IgG1;
- the light chain comprises a light chain variable region and a light chain constant region, wherein the light chain variable region has the amino acid sequence set forth in SEQ ID NO: 9 or SEQ ID NO: 10.
- the antibody or functional fragment thereof is a fully human antibody or a functional fragment thereof.
- said antibody or functional fragment thereof is a fully human antibody or a functional fragment thereof.
- the light chain constant region is a human k light chain constant region, e.g., having the amino acid sequence set forth in SEQ ID NO:11.
- the heavy chain constant region has the amino acid sequence set forth in SEQ ID NO: 8.
- the heavy chain has the amino acid sequence set forth in SEQ ID NO: 1 or 2.
- the light chain has the amino acid sequence set forth in SEQ ID NO: 3 or 4.
- the antibody or functional fragment thereof has ADCC activity.
- the antibody or a functional fragment thereof inhibits EGFR downstream phosphorylation. In still other embodiments, the antibody or functional fragment thereof inhibits EGFR signaling.
- the invention provides a nucleic acid molecule encoding an antibody or functional fragment thereof according to the invention.
- the nucleic acid molecule encodes a heavy chain and a light chain of an antibody of the invention or a functional fragment thereof.
- the nucleic acid molecule is an isolated nucleic acid molecule.
- the invention provides a combination of nucleic acid molecules comprising: encoding according to the foregoing A nucleic acid molecule of the light chain of any of the antibodies or functional fragments thereof, and a nucleic acid molecule encoding a heavy chain of an antibody or a functional fragment thereof according to any of the preceding claims.
- the combination of nucleic acid molecules is a combination of isolated nucleic acid molecules.
- the invention provides an immunoconjugate comprising an antibody of the invention or a functional fragment thereof conjugated to a therapeutic agent.
- the therapeutic agent is a toxin, a radioisotope, a drug, or a fine agent.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an antibody or functional fragment thereof according to the invention and/or an immunoconjugate according to the invention, and a pharmaceutically acceptable carrier.
- the invention provides a method of treating or preventing a disease or condition associated with aberrant expression of EGFR comprising administering to a subject an antibody, or a functional fragment, conjugate or pharmaceutical composition thereof, according to the invention.
- the disease or condition is a tumor associated disease.
- the tumor-related disease is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer, and bladder cancer.
- the invention provides methods of inhibiting EGFR downstream phosphorylation, inhibiting EGFR signaling, and/or increasing ADCC in a subject, comprising administering to the subject an antibody, or a functional fragment thereof, according to the invention, Compound or pharmaceutical composition.
- the invention provides a method or a functional fragment, nucleic acid molecule, nucleic acid molecule combination, conjugate or pharmaceutical composition according to the invention for use in the preparation or treatment of a disease or condition associated with aberrant expression of EGFR Use of the drug.
- the invention provides an antibody, or a functional fragment thereof, a nucleic acid molecule, a nucleic acid molecule combination, a conjugate or a pharmaceutical composition thereof, according to the invention, for use in the preparation of a method for inhibiting EGFR downstream phosphorylation, inhibiting EGFR signaling in a subject Use in transduction and/or drugs that increase ADCC.
- the invention provides an antibody, or a functional fragment thereof, a nucleic acid molecule, a nucleic acid molecule combination, a conjugate, or a pharmaceutical composition for use in treating or preventing a disease or condition associated with aberrant expression of EGFR, or in a subject Inhibition of EGFR downstream phosphorylation, inhibition of EGFR signaling, and/or increased ADCC.
- an antibody or functional fragment thereof according to the invention is isolated. Including the following steps:
- the synthetic DNA sequence can be synthesized by dividing into several fragments and then ligated into a complete fragment, or by using different primers, by PCR; 3) cloning the synthesized antibody DNA fragment into an expression plasmid;
- Figure 1 shows the results of PCR products for determining the sequences of the heavy and light chain variable regions.
- Figure 2 shows the SDS-PAGE gel to determine the protein electropherogram of the antibody.
- FIG. 3 is a schematic representation of the ELISA assay for binding of the EGFR antibody to EGFR-Fc.
- the results showed that YORK EGFR antibodies 1 and 2 have the same direct EGFR binding activity as panitumumab (SY-puni).
- Description Yongzhuo EGFR antibodies 1 and 2 recognize EGFR and have similar affinity to panitumumab.
- Figure 4 shows a schematic diagram of the ADCC activity measurement. The results showed that both YORK and EGFR antibodies 1 and 2 had similar ADCC activity to cetuximab, which was significantly higher than panitumumab.
- FIG. 5 shows a schematic representation of the inhibitory effect of EGFR antibodies on the downstream phosphorylation of EGFR.
- total (Tota l ) EGFR and phosphorylated EGFR were detected by Wes tern Blot.
- Tota l EGFR shows total EGFR levels, including phosphorylation and post-phospho EGFR.
- Above pEGFR shows phosphorylated EGFR content.
- Lane 1 for molecular weight marker; 2: PBS plus EGF; 3: PBS without EGF (2, 3 for PBS negative control); 4: Erbi tux without EGF; 5: Erbitux plus EGF; 6: Jia Yongzhuo EGFR antibody 1; 7: Jia Yongzhuo EGFR antibody 2; 8: Gapanicidumab (SY-puni).
- compositions are used interchangeably and mean at least one drug and optionally a pharmaceutically acceptable carrier that are combined together to achieve a particular purpose or A combination of excipients.
- the pharmaceutical compositions include combinations that are separated in time and/or space, as long as they are capable of acting together to achieve the objectives of the present invention.
- the components contained in the pharmaceutical composition e.g., antibodies, nucleic acid molecules, nucleic acid molecule combinations, and/or conjugates according to the present invention
- the components contained in the pharmaceutical composition are separately administered to a subject, the components may be administered to the subject simultaneously or sequentially.
- the pharmaceutically acceptable carrier is water, a buffered aqueous solution, an isotonic saline solution such as PBS (phosphate buffer), glucose, mannitol, dextrose, lactose, starch, magnesium stearate, fiber Or magnesium carbonate, 0.3% glycerol, hyaluronic acid, ethanol or polyalkylene glycol such as polypropylene glycol, triglyceride and the like.
- the type of pharmaceutically acceptable carrier employed depends inter alia on whether the composition according to the invention is formulated for oral, nasal, intradermal, subcutaneous, intramuscular or intravenous administration.
- the composition according to the invention may comprise a wetting agent, an emulsifier or a buffer substance as an additive.
- compositions, vaccine or pharmaceutical preparation according to the invention may be administered by any suitable route, for example, orally, nasally, intradermally, subcutaneously, intramuscularly or intravenously.
- terapéuticaally effective amount refers to a dose sufficient to demonstrate its benefit to the subject to which it is administered.
- the actual amount administered, as well as the rate and time course of administration, will depend on the condition and severity of the subject being treated. Prescriptions for treatment (eg, determination of dosage, etc.) are ultimately the responsibility of the GP and other physicians and rely on them to make decisions, usually considering the disease being treated, the condition of the individual patient, the site of delivery, the method of administration, and the Other factors known.
- disease or condition associated with aberrant expression of EGFR is intended to mean a disease or condition caused by aberrant expression of EGFR or characterized by aberrant expression of EGFR, preferably including but not limited to cancer.
- And/or tumors such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, Ovarian cancer, colon cancer, liver cancer, head and neck cancer, and bladder cancer.
- subject refers to a mammal, such as a human, but may also be other animals, such as wild animals (such as herons, donkeys, cranes, etc.), livestock (such as ducks, geese, etc.) or experimental animals (such as Orangutan, monkey, rat, mouse, rabbit, guinea pig, groundhog, ground ⁇ mouse, etc.).
- wild animals such as herons, donkeys, cranes, etc.
- livestock such as ducks, geese, etc.
- experimental animals such as Orangutan, monkey, rat, mouse, rabbit, guinea pig, groundhog, ground ⁇ mouse, etc.
- the term "functional fragment” as used herein especially refers to antibody fragments such as Fv, scFv (sc refers to single strand), Fab, F (ab, ) 2, Fab', scFv-Fc fragment or diabody (diabody), or Any fragment of half-life should be increased by chemical modification or by incorporation into liposomes, such as the addition of poly(alkylene) glycols such as polyethylene glycol (“PEGylated, PEGylated”) (referred to as Fv-PEG, s cFv-PEG, Fab-PEG, F (p2-PEG or PEGylated fragment of Fab-PEG) ("PEG” is polyethylene glycol), the fragment has EGFR binding activity.
- poly(alkylene) glycols such as polyethylene glycol (“PEGylated, PEGylated"
- the functional fragment will consist of or comprise a partial sequence of a heavy or light variable chain from which the antibody is derived, the partial sequence being sufficient to retain the same binding specificity and sufficient affinity as the antibody from which it is derived, EGFR, preferably at least equal to 1/100 of the affinity of the antibody from which it is derived, and in a more preferred manner at least equal to 1/10.
- This functional fragment will comprise a minimum of 5 amino acids, preferably 10, 15, 25, 50 of the antibody sequence from which it is derived. And 100 consecutive amino groups Acid.
- Example 1 Design and expression of YZ-EGFR VI and YZ-EGFR V2 antibody sequences
- the present invention can be used to prepare a full-human antibody of interest by a genetic engineering method well known to those skilled in the art.
- a genetic engineering method well known to those skilled in the art.
- the antibody of interest can also be produced by bacterial, yeast, viral and other eukaryotic cell expression systems, wherein the optimal preparation system is to use the Chinese ovarian hamster cell (CH0) stable cell line to prepare and produce the antibody.
- Fully human antibodies are produced by bacterial, yeast, viral and other eukaryotic cell expression systems, wherein the optimal preparation system is to use the Chinese ovarian hamster cell (CH0) stable cell line to prepare and produce the antibody.
- the original heavy chain IgG2 constant region sequence was changed to an IgG1 constant region sequence to form a YZ-EGFR v1 heavy chain sequence (SEQ ID No: 1).
- the unoptimized framework sequence of its original heavy chain variable region was changed to an optimized framework sequence (SEQ ID No: 6),
- YZ-EGFR v2 heavy chain sequence SEQ ID No: 2.
- the following is the sequence of the light chain variable region of panitumumab (SEQ ID No: 9), and the underlined portion is the framework sequence:
- the unoptimized framework sequence of its original light chain variable region was changed to an optimized framework sequence (SEQ ID No:
- DIQMTQSPSSLSASVGDRVTITCQASQDISNYLN WYQQKPGKAPKLLIY This is combined with the light chain constant region CL(k) sequence to form the light chain sequence of YZ-EGFR v2 (SEQ ID 4).
- This example describes the use of a method for transiently expressing 293-F cells, obtaining an antibody sample for assay, and also for producing an antibody of interest by bacteria, yeast, virus, and other eukaryotic cell expression systems, wherein the optimized preparation system is The human ovarian hamster cell (CH0) stable cell line was used to prepare and produce the whole human antibody.
- CH0 human ovarian hamster cell
- PCR primer oligonucleotide fragments encoding heavy and light chain variable region sequences were designed and synthesized. Adjacent oligonucleotide fragments overlap by about 18 bases, and PCR primer oligonucleotide fragments are typically about 54 bases in length. The same amount of each PCR primer fragment was mixed to carry out an overlap extension PCR reaction.
- the nucleic acid sequence of the primer fragment :
- Each antibody sequence has 8 (4 pairs) primer sequences, and each pair of primer sequences is used to prepare VH and VL small exons (mini-exon) of YZ-EGFR VI and YZ-EGFR V2 antibodies.
- Primer D 5' ATCACTTGCCCCTGGCATTCGGAGGCGGCACAAAGGTGGAGATTAAG Primer A 3' :
- V2-LC V2 light chain
- PCR reaction system dNTPs 0.2 ⁇ (final concentration); each PCR primer fragment 1 ⁇ buffer 3 ⁇ ⁇ ; cloned pfu (Invitrogen) 1 ⁇ 1 ; water to 30 ⁇ 1 .
- PCR reaction conditions After pre-denaturation at 94 ° C for 3 minutes, set denaturation at 94 ° C for 30 seconds, annealing at 56 ° C for 30 seconds, extension at 72 ° C for 1 minute, for 30 cycles, and finally 72. C extends for another 10 minutes.
- the PCR product was separated by 1% agarose gel electrophoresis, and the purified fragment was recovered. After digestion with EcoRI, it was cloned into pCR-Bluntll-TOPO (Invitrogen) vector and transformed into E. coli TOP010 (Invitrogen) on LB/Kanamycin plate. For screening, 10 white plaques were inoculated in LB liquid medium containing Kanamycin, and plasmids were extracted and sequenced using QIAGEN PCR purification kit to determine the heavy and light chain variable region sequences. . The PCR product is shown in Figure 1.
- RNA was isolated from normal human B cells, and the human IgG1 heavy chain constant region Fc fragment and the light chain constant region ⁇ fragment were obtained by PCR, and pre-constructed into pcDNA3.1 (Invitrogen) expression vector, and transformed by DH5 a bacteria. Positive clones were identified by plasmid extraction and sequencing.
- the heavy chain variable region of YZ-EGFR VI and YZ-EGFR V2 was excised from the positive clone of pCR-Bluntll-TOPO by Eco47III/NheI (from Invitrogen), and the clone was ligated into the pcDNA3.1-Fc expression vector.
- the light chain variable region of YZ-EGFR VI and YZ-EGFR V2 was excised from the positive clone of pCR-Bluntll-TOPO by AscI/BsiWI (from Invitrogen), and the clone was ligated into the pcDNA3.1- ⁇ expression vector. After again DH5 a bacterial transformation, plasmid extraction and sequencing of positive clones is determined. The sequencing results were consistent with the encoded sequences of the recorded antibodies.
- Y 1 YZ-EGFR VI and YZ-EGFR V2 light and heavy chain plasmids were co-transfected into 293-F fine-moon packets (293fectin, purchased from Invitrogen).
- the transfected cells were cultured in a 100 ml culture flask using FreeStyle 293 Express ion medium (purchased from Invitrogen) for 5 days.
- the culture supernatant was collected by centrifugation, 0.22 um membrane filtration, and subjected to Protein A column (5 ml MabSelect preloaded).
- the purity of the antibody was determined by SDS-PAGE (Fig. 2).
- the supernatant of the cell culture was collected twice and purified by Protein A.
- the purified antibody was dialyzed into PBS and the membrane was filtered through 0.22 for the membrane.
- Example 2 ELISA detects binding to EGFR
- Yongzhuo EGFR antibody-1 (YZ-EGFR VI); Yongzhuo EGFR antibody-2 (YZ-EGFR V2); panitumumab (SY-puni from Amgen); EGFR-Fc (from Thermo Fi sher) Method: Determine by direct ELISA as follows:
- ELISA plates were coated with 1 g/ml EGFR-Fc at 50 ⁇ /well and overnight at 4 °C (about 16 hours).
- step 6 Add the antibody to the EGFR-Fc-coated ELISA plate (see steps 1-3) at different concentrations (according to step 5), incubate at 50 ⁇ /well, incubate at 37 °C for 1 hour, and repeat the assay once.
- Figure 3 shows that both YORK EGFR antibodies 1 and 2 have the same direct EGFR binding activity as panitumumab (SY-puni), indicating that YORK EGFR antibodies 1 and 2 recognize EGFR and have similar affinity to panitumumab.
- Example 3 ADCC reaction of anti-EGFR antibody in vitro
- Yongzhuo EGFR antibody-1 (YZ-EGFR VI); Yongzhuo EGFR antibody-2 (YZ-EGFR V2); Panitumab (SY-puni, from Amgen); Erbitux (cetuximab, from Imclone; Calcein-AM (Invitrogen); round bottom 96-well plate (BD Scientific), peripheral blood mononuclear cells (PBMC) purchased from AllCells (health donor).
- PBMC peripheral blood mononuclear cells
- A431 human epidermal carcinoma cells
- step 2 add PBMC effector cells from a healthy donor source.
- the final effect is a ratio of target cells (labeled A431) to effector cells (PBMC) of 40:1 at a final volume of 200 ul/well.
- Figure 4 shows that both YORK EGFR antibodies 1 and 2 have similar ADCC activity to cetuximab and are significantly higher than panitumumab.
- Yongzhuo EGFR antibody-1 (YZ-EGFR VI); Yongzhuo EGFR antibody-2 (YZ-EGFR V2); Panitumab (SY_puni from Amgen); Erbitux (erbitux, cetuximab from Imclone) A431 cells (from ATCC: CRL-2592); recombinant human epidermal growth factor (from R&D); cell lysis buffer (10 X) (from Cell Signalling); BCA kit (from Pierce); anti-pEGFR (pY 1068) and pan-anti-EGFR (from CST).
- the real 3 (Tota l ) EGFR and phosphorylated EGFR were detected by Wes tern Blot.
- the bottom panel in Figure 5 Tota l EGFR shows total EGFR levels, including phosphorylation and post-phospho EGFR. Above pEGFR shows phosphorylated EGFR levels.
- Figure 5 shows that in the absence of total EGFR (bottom panel), YORK EGFR antibodies 1 and 2, erbi tux and panitumumab (SY-puni) are able to significantly inhibit EGFR downstream phosphorylation, thereby Blocking the signaling pathway further demonstrates that YORK EGFR antibodies 1 and 2 have EGFR binding, inhibition of downstream signaling pathways, and tumor cell inhibition.
- a positive control for total antibodies and a negative control for PBS demonstrate the effectiveness of this experiment.
- panifumab an anti-EGFR antibody that concentrates on the advantages of many different antibody products of the prior art has been successfully obtained.
- the antibody of the present invention is
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13881974.3A EP2985292A4 (en) | 2013-04-07 | 2013-04-07 | ANTIBODY OF THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR |
BR112015025549A BR112015025549A2 (pt) | 2013-04-07 | 2013-04-07 | anticorpo contra o receptor do fator de crescimento epidérmico |
RU2015147913A RU2652880C2 (ru) | 2013-04-07 | 2013-04-07 | Антитело против рецептора эпидермального фактора роста |
PCT/CN2013/073811 WO2014166029A1 (zh) | 2013-04-07 | 2013-04-07 | 针对表皮生长因子受体的抗体 |
US14/876,053 US9644031B2 (en) | 2013-04-07 | 2015-10-06 | Epidermal growth factor receptor antibody |
ZA2015/08035A ZA201508035B (en) | 2013-04-07 | 2015-10-29 | Epidermal growth factor receptor antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/073811 WO2014166029A1 (zh) | 2013-04-07 | 2013-04-07 | 针对表皮生长因子受体的抗体 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/876,053 Continuation US9644031B2 (en) | 2013-04-07 | 2015-10-06 | Epidermal growth factor receptor antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014166029A1 true WO2014166029A1 (zh) | 2014-10-16 |
Family
ID=51688811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/073811 WO2014166029A1 (zh) | 2013-04-07 | 2013-04-07 | 针对表皮生长因子受体的抗体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9644031B2 (zh) |
EP (1) | EP2985292A4 (zh) |
BR (1) | BR112015025549A2 (zh) |
RU (1) | RU2652880C2 (zh) |
WO (1) | WO2014166029A1 (zh) |
ZA (1) | ZA201508035B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3011746A1 (en) | 2016-02-06 | 2017-08-10 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
EP3820895A4 (en) * | 2018-07-09 | 2022-04-27 | Shanghai Epimab Biotherapeutics Co., Ltd. | EFFICIENTLY EXPRESSED EGFR AND PD-L1 BINDER PROTEINS |
WO2020084608A1 (en) * | 2018-10-22 | 2020-04-30 | Explore Bio 1 Ltd | Precursor bispecific antibody constructs and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03011365A (es) * | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
EP2332990A1 (en) * | 2004-03-19 | 2011-06-15 | Imclone LLC | Human anti-epidermal growth factor receptor antibody |
AU2007254942B2 (en) * | 2006-06-02 | 2011-10-27 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
US9029508B2 (en) * | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102112494A (zh) * | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
JP5674654B2 (ja) * | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用 |
WO2012064733A2 (en) * | 2010-11-09 | 2012-05-18 | Medimmune, Llc | Antibody scaffold for homogenous conjugation |
EP2694552B1 (en) * | 2011-04-07 | 2017-10-11 | Amgen Inc. | Novel egfr binding proteins |
CN103172741B (zh) * | 2011-12-20 | 2018-04-27 | 智翔(上海)医药科技有限公司 | 全人源抗egfr抗体 |
-
2013
- 2013-04-07 BR BR112015025549A patent/BR112015025549A2/pt not_active Application Discontinuation
- 2013-04-07 EP EP13881974.3A patent/EP2985292A4/en not_active Withdrawn
- 2013-04-07 RU RU2015147913A patent/RU2652880C2/ru not_active IP Right Cessation
- 2013-04-07 WO PCT/CN2013/073811 patent/WO2014166029A1/zh active Application Filing
-
2015
- 2015-10-06 US US14/876,053 patent/US9644031B2/en not_active Expired - Fee Related
- 2015-10-29 ZA ZA2015/08035A patent/ZA201508035B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO2011028811A2 (en) * | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
Non-Patent Citations (10)
Title |
---|
BLEEKER WK; LAMMERTS VAN BUEREN JJ; VAN OJIK HH; GERRITSEN AF; PLUYTER M; HOUTKAMP M; HALK E; GOLDSTEIN J; SCHUURMAN J; VAN DIJK M: "Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy", J IMMUNOL, vol. 173, 2004, pages 4699 - 707, XP002358777 |
CASTILLO L; ETIENNE-GRIMALDI MC; FISCHEL JL ET AL.: "Pharmacological background of EGFR targeting", ANN ONCOL, vol. 15, 2004, pages 1007 - 1012, XP002402776, DOI: doi:10.1093/annonc/mdh257 |
JORISSEN RN; WALKER F; POULIOT N ET AL.: "Epidermal growth factor receptor: mechanisms of activation and signaling", EXP CELL RES, vol. 284, 2003, pages 31 - 53 |
KABAT ET AL.: "SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST", 1991, NATIONAL INSTITUTES OF HEALTH |
MENDELSOHN J; BASELGA J: "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer", J CLIN ONCOL, vol. 21, 2003, pages 2787 - 2799 |
OLAYIOYE MA; NEVE RM; LANE HA ET AL.: "The EerbB Signaling network: receptor heterodimerzat ion in development and cancer", THE EMBO J, vol. 19, 2000, pages 3159 - 3167 |
PATEL D; GUO X; NG S; MELCHIOR M; BALDERES P; BURTRUM D; PERSAUD K; LUNA X; LUDWIG DL; KANG X: "IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab", HUM ANTIBODIES, vol. 19, 2010, pages 89 - 99, XP009172959, DOI: doi:10.3233/HAB-2010-0232 |
SCHNEIDER-MERCK, T. ET AL.: "Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage", J IMMUNOL., vol. 184, no. 1, 1 January 2010 (2010-01-01), pages 512 - 520, XP055270382 * |
See also references of EP2985292A4 |
Z STEPLEWSKI; L K SUN; C W SHEARMAN; J GHRAYEB; P DADDONA; H KOPROWSKI: "Biological Activity of Human-Mouse IgGl, IgG2, IgG3, and IgG4 chimeric monoclonal Antibodies with antitumor specificity", PNAS, vol. 85, 1988, pages 4852 - 4856, XP001007415, DOI: doi:10.1073/pnas.85.13.4852 |
Also Published As
Publication number | Publication date |
---|---|
EP2985292A4 (en) | 2016-12-21 |
EP2985292A1 (en) | 2016-02-17 |
US20160017045A1 (en) | 2016-01-21 |
RU2015147913A (ru) | 2017-05-15 |
ZA201508035B (en) | 2018-05-30 |
RU2652880C2 (ru) | 2018-05-03 |
US9644031B2 (en) | 2017-05-09 |
BR112015025549A2 (pt) | 2017-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7374995B2 (ja) | 抗pd-1/抗vegfa二官能性抗体、その医薬組成物およびその使用 | |
JP2017506217A (ja) | 標的TGFβ阻害 | |
JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体(ron)の阻害 | |
US9822174B2 (en) | Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
ES2699584T3 (es) | Anticuerpos multifuncionales que se unen a EGFR y MET | |
US10759859B2 (en) | Anti-PD-1 antibodies and uses thereof | |
WO2021062406A1 (en) | Cytokine prodrugs and dual-prodrugs | |
CN114269782B (zh) | 抗tigit抗体及其应用 | |
WO2019114793A1 (zh) | 一种egfr抗体及其制备方法和应用 | |
US9644031B2 (en) | Epidermal growth factor receptor antibody | |
CN103172741B (zh) | 全人源抗egfr抗体 | |
WO2020014098A9 (en) | Efficiently expressed egfr and pd-l1 bispecific binding proteins | |
TW202334228A (zh) | B7h6抗體及其應用 | |
AU2021403263B2 (en) | Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof | |
WO2021244553A1 (zh) | 一种抗pd-l1和egfr的四价双特异性抗体 | |
CN112175087B (zh) | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 | |
CN106963950B (zh) | 用于***的联合用药物 | |
KR20130057959A (ko) | 항 her2 단일클론항체와 il-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물 | |
WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
US20240052065A1 (en) | Binding molecules for the treatment of cancer | |
CN117510641A (zh) | 靶向cd112r和tigit的双特异性抗体及其用途 | |
KR101631646B1 (ko) | VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체 | |
EP4277922A2 (en) | Chimeric molecules comprising il-12 agonist polypeptide | |
CN112867737A (zh) | 抗cd137抗体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13881974 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013881974 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015147913 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015025549 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015025549 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151006 |